Ghebrehiwet Merhawit, Pavlis Janelle, Gomez-Meade Carlos
College of Medicine, Oklahoma State University Center for Health Sciences, Tulsa, USA.
Dermatology, Oklahoma Cancer Specialists and Research Institute, Tulsa, USA.
Cureus. 2024 Sep 17;16(9):e69605. doi: 10.7759/cureus.69605. eCollection 2024 Sep.
Melanoma, characterized by its aggressive nature and tendency for metastasis, presents a significant challenge in clinical management. While surgical excision remains the gold standard for localized disease, therapeutic advancements for advanced stages are crucial. Oncolytic virotherapy, exemplified by Talimogene laherparepvec (T-VEC), offers a potential approach. Here, we present a 79-year-old male with advanced melanoma on the left distal thumb who opted for T-VEC therapy over surgical excision. Over 18 sessions, T-VEC demonstrated efficacy, resulting in lesion regression and no evidence of recurrence upon long-term monitoring. This case emphasizes the potential of T-VEC in advanced melanoma management, leveraging its dual mechanism targeting primary and metastatic lesions while harnessing immune response. Safety considerations and further investigations into potential interactions with other immunotherapies are warranted to optimize treatment strategies and ensure patient well-being. As oncolytic virotherapy continues to evolve, T-VEC stands as a potential option for the treatment of advanced melanoma.
黑色素瘤具有侵袭性和转移倾向，给临床治疗带来了重大挑战。虽然手术切除仍是局限性疾病的金标准，但晚期疾病的治疗进展至关重要。以Talimogene laherparepvec（T-VEC）为代表的溶瘤病毒疗法提供了一种潜在的治疗方法。在此，我们报告一例79岁男性，左拇指远端患有晚期黑色素瘤，他选择了T-VEC治疗而非手术切除。在超过18个疗程中，T-VEC显示出疗效，导致病灶消退，长期监测未发现复发迹象。该病例强调了T-VEC在晚期黑色素瘤治疗中的潜力，它利用其双重机制靶向原发性和转移性病灶，同时激发免疫反应。有必要考虑安全性，并进一步研究其与其他免疫疗法的潜在相互作用，以优化治疗策略并确保患者的健康。随着溶瘤病毒疗法的不断发展，T-VEC是治疗晚期黑色素瘤的一个潜在选择。
